State Street Corp purchased a new stake in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 58,046 shares of the company's stock, valued at approximately $1,189,000. State Street Corp owned about 0.16% of Rapport Therapeutics at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. purchased a new position in Rapport Therapeutics in the 3rd quarter worth $1,498,000. Millennium Management LLC purchased a new position in shares of Rapport Therapeutics in the second quarter worth about $2,716,000. Perceptive Advisors LLC bought a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at about $17,403,000. ARCH Venture Management LLC purchased a new stake in Rapport Therapeutics during the 2nd quarter valued at about $86,730,000. Finally, TD Asset Management Inc bought a new position in Rapport Therapeutics during the 2nd quarter worth approximately $2,361,000.
Rapport Therapeutics Stock Performance
RAPP stock traded up $1.09 during midday trading on Friday, hitting $19.48. The company had a trading volume of 108,688 shares, compared to its average volume of 97,794. Rapport Therapeutics has a 52 week low of $16.55 and a 52 week high of $29.74. The firm has a 50 day moving average price of $21.60.
About Rapport Therapeutics
(
Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
